Last $713.96 MXN
Change Today 0.00 / 0.00%
Volume 0.0
TEVAN On Other Exchanges
Symbol
Exchange
New York
Tel Aviv
OTC US
Mexico
Frankfurt
As of 4:09 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVAN) Snapshot

Open
$713.96
Previous Close
$713.96
Day High
$713.96
Day Low
$713.96
52 Week High
07/22/14 - $713.96
52 Week Low
08/6/13 - $484.00
Market Cap
607.6B
Average Volume 10 Days
500.0
EPS TTM
--
Shares Outstanding
851.0M
EX-Date
05/16/14
P/E TM
--
Dividend
$1.40
Dividend Yield
2.45%
Current Stock Chart for TEVA PHARMACEUTICAL-SP ADR (TEVAN)

teva pharmaceutical-sp adr (TEVAN) Details

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Its products include Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Provigil and Nuvigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. The company also offers Treanda to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim that stimulate the production of white blood cells; Lonquex, which reduces the duration of neutropenia and incidence of febrile neutropenia in adult patients; Eporatio that stimulates the production of red blood cells; and Synribo for chronic myeloid leukemia. In addition, it provides ProAir for the treatment of bronchospasm; QVAR for the treatment of asthma; Qnasl Nasal Aerosol for nasal allergy symptoms in adults; Plan B One-Step and Quartette, which prevents pregnancy; Seasonique and LoSeasonique that are extended-cycle oral contraceptives; Zoely, a regimen combination contraceptive oral pill; and ParaGard, a non-hormonal intrauterine contraceptive. Further, the company offers Enjuvia for vasomotor symptoms associated with menopause; hormone therapy treatments for menopause/perimenopause; therapies for infertility and urinary incontinence; and manufactures active pharmaceutical ingredients. It also distributes third party products. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

44,945 Employees
Last Reported Date: 02/10/14
Founded in 1901

teva pharmaceutical-sp adr (TEVAN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical-sp adr (TEVAN) Key Developments

Teva Pharmaceutical Industries Limited Announces FDA Acceptance of NDA Filing for Investigational Short-Acting Beta-Agonist Inhaler

Teva Pharmaceuticals Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug application (NDA) for albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm (EIB) in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents (12 years of age and older) with asthma and exercise-induced bronchospasm (EIB). The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.

Teva Pharmaceutical Industries Ltd. Files US Food and Drug Administration Citizen Petition on Copaxone

Teva Pharmaceutical Industries Ltd. has filed a citizen petition with the US Food and Drug Administration (FDA) regarding the approvability of generic versions of Copaxone. Teva submitted the petition according to the FDA's procedural guidance and in accordance with the FDA's desire to facilitate public review and comment regarding new scientific data on gene expression. Teva has in fact previously submitted much of this information in its Copaxone New Drug Application (NDA) and the FDA asked Teva to resubmit the information as a petition. Teva's petition provides new scientific data on gene expression and evidence to support arguments regarding active ingredient sameness, immunogenicity and bioequivalence testing with regard to its relapsing-remitting multiple sclerosis medicine Copaxone. As Teva's data show, it would be contrary to the public's health and welfare to approve a purported generic glatiramer acetate product that, based on current analytical technologies and confirmed by techniques such as gene expression evaluation, at best can be shown to be similar, but clearly not the same as Copaxone. Teva's position is that any potential generic version of Copaxone should use the same gene expression markers and biological pathways to demonstrate sameness, as well as be evaluated via pre-clinical testing and full-scale, placebo-controlled clinical trials with measured clinical endpoints (such as relapse rate) in patients with relapsing forms of multiple sclerosis to establish safety, efficacy and immunogenicity.

Teva Pharmaceutical Updates on U.S. Court of Appeals Uphold Ruling Confirming Invalidity of Baraclude Patent

Teva Pharmaceutical Industries has reported that the U.S. Court of Appeals for the Federal Circuit upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb's entecavir compound claim of U.S. Patent No. 5,206,244 invalid. Teva's ANDA for entecavir has received tentative approval from the U.S. Food and Drug Administration (FDA). Teva will finalize the launch plans for this product once it receives final approval from the FDA.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVAN:MM $713.96 MXN 0.00

TEVAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.89 USD -0.08
AbbVie Inc $54.08 USD -0.40
Baxter International Inc $77.00 USD +0.16
Bristol-Myers Squibb Co $49.46 USD +0.14
Eli Lilly & Co $64.37 USD +0.12
View Industry Companies
 

Industry Analysis

TEVAN

Industry Average

Valuation TEVAN Industry Range
Price/Earnings 33.8x
Price/Sales 2.3x
Price/Book 2.0x
Price/Cash Flow 37.9x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.